Aktis Oncology (NASDAQ:AKTS) Given New $33.00 Price Target at HC Wainwright

Aktis Oncology (NASDAQ:AKTS) had its price objective raised by equities researchers at HC Wainwright from $30.00 to $33.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the technology company’s stock. HC Wainwright’s target price indicates a potential upside of 99.52% from the company’s current price.

A number of other brokerages also recently issued reports on AKTS. JPMorgan Chase & Co. began coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 price target on the stock. Wall Street Zen upgraded shares of Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th. TD Cowen assumed coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They set a “buy” rating on the stock. Bank of America initiated coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They set a “buy” rating and a $34.00 target price on the stock. Finally, Leerink Partners began coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They issued an “outperform” rating and a $31.00 price target for the company. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $32.00.

Aktis Oncology Stock Performance

Aktis Oncology stock opened at $16.54 on Tuesday. Aktis Oncology has a 12 month low of $14.72 and a 12 month high of $29.16. The stock has a 50 day moving average of $19.21.

Insider Transactions at Aktis Oncology

In related news, Director Ecor1 Capital, Llc purchased 2,222,222 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was bought at an average price of $18.00 per share, with a total value of $39,999,996.00. Following the acquisition, the director owned 4,348,658 shares in the company, valued at $78,275,844. The trade was a 104.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Helen Susan Kim acquired 835,000 shares of Aktis Oncology stock in a transaction on Monday, January 12th. The shares were bought at an average price of $18.00 per share, with a total value of $15,030,000.00. Following the completion of the transaction, the director directly owned 5,671,825 shares of the company’s stock, valued at $102,092,850. This trade represents a 17.26% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 6,117,776 shares of company stock worth $110,119,968 in the last ninety days.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.